Presentation is loading. Please wait.

Presentation is loading. Please wait.

Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes  Stuart E. Samuels, MD, PhD, Matthew.

Published byLiliana Ford Modified over 6 years ago

Similar presentations

Presentation on theme: "Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes  Stuart E. Samuels, MD, PhD, Matthew."— Presentation transcript:

1 Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes  Stuart E. Samuels, MD, PhD, Matthew H. Stenmark, MD, Jae Y. Lee, MD, PhD, Jonathan B. McHugh, MD, James A. Hayman, MD, Mark B. Orringer, MD, Susan G. Urba, MD, Libin Sun, MD, Congying Xie, PhD, Feng-Ming Kong, MD, PhD, Kyle C. Cuneo, MD  Advances in Radiation Oncology  Volume 2, Issue 3, Pages (July 2017) DOI: /j.adro Copyright © 2017 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions

2 Figure 1 Kaplan-Meier curves for evaluable patients with a complete response, near complete response, and partial response according to the Becker criteria8 following neoadjuvant twice-daily chemoradiation for esophageal cancer. All pathological specimens were reviewed and graded by a single pathologist. Figures for (A) overall survival, (B) progression-free survival (PFS), (C) locoregional control, and (D) distant control are shown. Advances in Radiation Oncology 2017 2, DOI: ( /j.adro ) Copyright © 2017 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions

3 Figure 2 Kaplan-Meier curve with 95% confidence interval for overall survival (OS) in patients with esophageal cancer undergoing neoadjuvant twice-daily chemoradiation therapy. The median follow-up for surviving patients was 59 months. For the entire group, the median OS was 28 months and 3-year OS was 44%. Advances in Radiation Oncology 2017 2, DOI: ( /j.adro ) Copyright © 2017 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions

4 Figure 3 Comparison of overall survival and treatment related mortality for esophageal cancer. Shown are the reported outcomes from our series compared to outcomes from the studies performed by EORTC14, Walsh et al.11, Stahl et al.13, TROG15, and the CROSS Trial1. Advances in Radiation Oncology 2017 2, DOI: ( /j.adro ) Copyright © 2017 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions

Download ppt "Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes  Stuart E. Samuels, MD, PhD, Matthew."

Similar presentations

Neutron radiation therapy for advanced thyroid cancers Tobias R. Chapman, MD, George E. Laramore, PhD, MD, Stephen R. Bowen, PhD, Peter F. Orio, DO, MS.

Neutron radiation therapy for advanced thyroid cancers Tobias R. Chapman, MD, George E. Laramore, PhD, MD, Stephen R. Bowen, PhD, Peter F. Orio, DO, MS.
Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer  Victor E. Chen, BS, Erin.

Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer  Victor E. Chen, BS, Erin.
John Boyle, MD, Brad Ackerson, MD, Lin Gu, MS, Chris R. Kelsey, MD 

John Boyle, MD, Brad Ackerson, MD, Lin Gu, MS, Chris R. Kelsey, MD 
Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports  Daniel K. Ebner, BS, Tadashi Kamada, MD, PhD,

Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports  Daniel K. Ebner, BS, Tadashi Kamada, MD, PhD,
Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity  Sarah J. Stephens, MD, Samantha Thomas, MB,

Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity  Sarah J. Stephens, MD, Samantha Thomas, MB,
Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions  Chelsea.

Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions  Chelsea.
Efficacy and toxicity of rectal cancer reirradiation using IMRT for patients who have received prior pelvic radiation therapy  Fady F. Youssef, MS, Parag.

Efficacy and toxicity of rectal cancer reirradiation using IMRT for patients who have received prior pelvic radiation therapy  Fady F. Youssef, MS, Parag.
Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial  Susanne M.

Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial  Susanne M.
A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy  William.

A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy  William.
Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and.

Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and.
Tijana Skrepnik, MD, Silvija Gottesman, MD, Baldassarre Stea, MD, PhD 

Tijana Skrepnik, MD, Silvija Gottesman, MD, Baldassarre Stea, MD, PhD 
Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H

Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H
Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma  Arianna.

Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma  Arianna.
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
Volume 148, Issue 1, Pages (January 2018)

Volume 148, Issue 1, Pages (January 2018)
Nirav S. Kapadia, MD, MS, Luca F. Valle, MD, Julie A

Nirav S. Kapadia, MD, MS, Luca F. Valle, MD, Julie A
Prognostic Value of Primary Tumor Volume Changes on kV-CBCT during Definitive Chemoradiotherapy for Stage III Non–Small Cell Lung Cancer  Patrick Wald,

Prognostic Value of Primary Tumor Volume Changes on kV-CBCT during Definitive Chemoradiotherapy for Stage III Non–Small Cell Lung Cancer  Patrick Wald,
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non–Small Cell Lung Cancer: A Phase II Clinical Trial 

Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non–Small Cell Lung Cancer: A Phase II Clinical Trial 

Similar presentations

Ads by Google